Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium

Mourits, Marian J.E.; Hollema, Harmen; Vries, de Elisabeth G. E.; Hoor, KA Ten; Willemse, Phb; Zee, van der Ate

doi:10.1053/hupa.2002.32226

Cited by 23 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the expression of inhibin/ activin a and b in polyps was found to be similar in both groups (Mylonas et al 2004). Furthermore, the apoptosis/proliferation index, determined by measuring the proliferation marker Ki67 and the apoptosis markers Fas, FasL and Bcl-2, is higher in benign endometria of tamoxifen users compared with endometria of non-users (Mourits et al 2002a(Mourits et al , 2002b.…”

Section: Introductionmentioning

confidence: 71%

Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study

Gielen¹,

Kühne²,

Ewing³

et al. 2005

Endocr Relat Cancer

View full text Add to dashboard Cite

Tamoxifen treatment for breast cancer increases proliferation of the endometrium, resulting in an enhanced prevalence of endometrial pathologies, including endometrial cancer. An exploratory study was performed to begin to understand the molecular mechanism of tamoxifen action in the endometrium. Gene-expression profiles were generated of endometrial samples of tamoxifen users and compared with matched controls. The pathological classification of samples from both groups included atrophic/inactive endometrium and endometrial polyps. Unsupervised clustering revealed that samples of tamoxifen users were, irrespective of pathological classification, fairly similar and consequently form a subgroup distinct from the matched controls. Using SAM analysis (a statistical method to select genes differentially expressed between groups), 256 differentially expressed genes were selected between the tamoxifen and control groups. Upon comparing these genes with oestrogen-regulated genes, identified under similar circumstances, 95% of the differentially expressed genes turned out to be tamoxifen-specific. Finally, construction of a gene-expression network of the differentially expressed genes revealed that 69 genes centred around five well-known genes: TP53, RELA, MYC, epidermal growth factor receptor and b-catenin. This could indicate that these well-known genes, and the pathways in which they function, are important for tamoxifencontrolled proliferation of the endometrium.

show abstract

Section: Introductionmentioning

confidence: 71%

Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study

Gielen¹,

Kühne²,

Ewing³

et al. 2005

Endocr Relat Cancer

View full text Add to dashboard Cite

show abstract

“…Recent studies have also shown that increasing levels of tamoxifen may switch the mode of cell death from autophagy to apoptosis and finally to necrosis in a breast cancer cell line, suggesting that the toxic effects of tamoxifen are concentrationdependent (Bursch et al, 2008). However, no increased level of apoptosis in the endometrium has been reported in tamoxifen users (Mourits et al, 2002).…”

Section: Andersson Et Almentioning

confidence: 99%

Tamoxifen-Induced Adduct Formation and Cell Stress in Human Endometrial Glands

Andersson

Helmestam²,

Żebrowska³

et al. 2009

Drug Metab Dispos

View full text Add to dashboard Cite

show abstract

“…Similarly, in vivo, tamoxifen causes an increase of cell proliferation, which results in a high Ki67 proliferation index, and a stimulation of the anti-apoptotic pathway (Fas, FasL and Bcl2) [22]. Several recent studies have suggested that the UPR and mTOR signaling pathways are activated in long-term tamoxifen exposure-induced endometrial cancer [20,23,24].…”

Section: Pathophysiologymentioning

confidence: 99%

Tamoxifen Treatment and Risk of Endometrial Cancer: An Overview

Kouhen¹,

Rais²,

Benhmidou³

et al. 2016

JHS

View full text Add to dashboard Cite

For several decades, tamoxifen has proven effective in reducing recurrence and mortality for early and metastatic breast cancer with positive estrogen receptors, and has been proven to be beneficial in preventing breast cancer in high-risk women. However, tamoxifen has been associated with an increased risk of endometrial cancer by its agonist effects on the endometrium in postmenopausal women. The purpose of this article, through an exhaustive summary of literature, is to provide a better understanding of this relationship and its impact on managed care on patients.

show abstract

Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium

Cited by 23 publications

References 25 publications

Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study

Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study

Tamoxifen-Induced Adduct Formation and Cell Stress in Human Endometrial Glands

Tamoxifen Treatment and Risk of Endometrial Cancer: An Overview

Contact Info

Product

Resources

About